Marjorie C Meyer1, Anne M Johnston, Abigail M Crocker, Sarah H Heil. 1. From the Department of Obstetrics, Gynecology and Reproductive Sciences (MCM), Department of Pediatrics (AMJ), Department of Mathematics and Statistics (AMC), and Departments of Psychiatry and Psychology (SHH), University of Vermont, Burlington, VT.
Abstract
OBJECTIVES: To compare maternal characteristics, prenatal care, and newborn outcomes in a cohort of opioid-dependent pregnant women treated with methadone versus buprenorphine. METHODS: In a retrospective cohort study, 609 pregnant, opioid-dependent women were treated with methadone (n = 248) or buprenorphine (n = 361) between 2000 and 2012 at a single institution. RESULTS: Mothers treated with buprenorphine were more likely to start medication before or earlier in pregnancy, had longer gestation, and gave birth to larger infants. Newborns of buprenorphine- versus methadone-maintained mothers required treatment for neonatal abstinence significantly less often and for a shorter duration. CONCLUSIONS: These data suggest pregnancy outcomes with buprenorphine to treat opioid dependence during pregnancy in clinical practice are as good and often better than outcomes with methadone. These results are consistent with efficacy data from randomized clinical trials and further support the use of buprenorphine for the treatment of opioid dependence during pregnancy.
OBJECTIVES: To compare maternal characteristics, prenatal care, and newborn outcomes in a cohort of opioid-dependent pregnant women treated with methadone versus buprenorphine. METHODS: In a retrospective cohort study, 609 pregnant, opioid-dependent women were treated with methadone (n = 248) or buprenorphine (n = 361) between 2000 and 2012 at a single institution. RESULTS: Mothers treated with buprenorphine were more likely to start medication before or earlier in pregnancy, had longer gestation, and gave birth to larger infants. Newborns of buprenorphine- versus methadone-maintained mothers required treatment for neonatal abstinence significantly less often and for a shorter duration. CONCLUSIONS: These data suggest pregnancy outcomes with buprenorphine to treat opioid dependence during pregnancy in clinical practice are as good and often better than outcomes with methadone. These results are consistent with efficacy data from randomized clinical trials and further support the use of buprenorphine for the treatment of opioid dependence during pregnancy.
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio Journal: Drug Alcohol Depend Date: 2005-07 Impact factor: 4.492
Authors: Johan Kakko; Leif Grönbladh; Kerstin Dybrandt Svanborg; Joachim von Wachenfeldt; Christian Rück; Bob Rawlings; Lars-Håkan Nilsson; Markus Heilig Journal: Am J Psychiatry Date: 2007-05 Impact factor: 18.112
Authors: Jennifer N Lind; Julia D Interrante; Elizabeth C Ailes; Suzanne M Gilboa; Sara Khan; Meghan T Frey; April L Dawson; Margaret A Honein; Nicole F Dowling; Hilda Razzaghi; Andreea A Creanga; Cheryl S Broussard Journal: Pediatrics Date: 2017-06 Impact factor: 7.124
Authors: Lara S Lemon; Ashley Naimi; Steve N Caritis; Robert W Platt; Raman Venkataramanan; Lisa M Bodnar Journal: Paediatr Perinat Epidemiol Date: 2018-01-26 Impact factor: 3.980